Azilect® (rasagiline mesylate)
Azilect ® information courtesy of Teva Pharmaceuticals Ltd and H.Lundbeck A/S
Last updated 23 June 2008
This section provides a summary of the drug information for Azilect® (rasagiline mesylate). It is still important that you read the full package leaflet that accompanies the product carefully before you start to take any medication. If you have any further questions about your Pd medication, or other aspects of your Pd treatment, you should discuss these with your doctor or other healthcare professional.

Azilect® 1 mg tablets
Azilect® is registered for use in the following countries

Austria
Belgium
Canada
Croatia
Denmark
Estonia
Finland
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lithuania
Luxembourg
Malta
Mexico
Netherlands
Norway
Poland
Romania
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
United Kingdom
USA
Availability - Formulation
Azilect® 1 mg tablets
What Does It Contain?
- The active ingredient in Azilect® is rasagiline mesilate. Other ingredients are mannitol, colloidal anhydrous silica, maize starch, pregelatinised maize starch, stearic acid, talc.
Therapeutic Indication (Who Is It For?)
Azilect® is a medicine for the treatment of Parkinson’s disease. It belongs to a class of treatments called monoamine oxidase Type B (MAOB) inhibitors.
Azilect® works by blocking the breakdown of dopamine by the enzyme Monoamine Oxidase-B in the brain, keeping it ‘available’ for longer. Azilect® can be taken early in Parkinson’s disease on its own (as ‘monotherapy’) to help boost dopamine still being produced by the brain, and/or later in the disease, to boost the effect of levodopa (as ‘adjunct therapy’).
Contra-indications (When Not To Use)
Most people can take Azilect®, but you should be sure to tell your doctor if:
- you take antidepressants, unselective MAO inhibitors or the painkiller pethidine
- have liver problems, or
- if you are allergic to any of the ingredients of Azilect®.
Special Warning & Precautions For Use
- Most people can take Azilect®, but you should be sure to tell your doctor if you take antidepressants or the painkiller pethidine, have liver problems, could become pregnant, or if you are allergic to any of the ingredients of Azilect®.
- Most medicines can be taken along with Azilect®, but do tell any doctor or pharmacist that you are taking this treatment, as there are some medicines that need special consideration. You should tell your doctor about all medicines that you are currently taking, even those obtained without prescription such as cough suppressants, nasal and oral decongestants, and natural products such as St John's Wort etc..
How To Take Azilect®
- Like all medicines, Azilect® should be taken as instructed by your doctor. The dose is one tablet taken once a day with or without food.
- If you forget to take a dose, make sure you take the next one at the usual time. Do not take a double dose to cover the one you missed.
- Azilect® should be taken for as long as your doctor believes it is necessary. Your doctor will monitor your progress on Azilect® and assess how long you need to continue. Always report any concerns you may have about your treatment, as this will help your doctor to understand how you are getting on, and how to manage your treatment most effectively.
Interaction With Other Medicinal Products & Other Forms of Interaction
- Rasagiline should not be administered along with other MAO inhibitors as there may be a risk of non-selective MAO inhibition that may lead to hypertensive crises.
- The concomitant use of rasagiline and fluoxetine or fluvoxamine should be avoided. With MAO inhibitors as well as with another selective MAO-B inhibitor there have been reports of drug interactions with the concomitant use of sympathomimetic medicinal products. Therefore, in view of the MAO inhibitory activity of rasagiline, concomitant administration of rasagiline and sympathomimetics such as those present in nasal and oral decongestants or cold medications, containing ephedrine or pseudoephedrine, is not recommended.
- There have been reports of drug interactions with the concomitant use of dextromethorphan and non-selective MAO inhibitors. Therefore, in view of the MAO inhibitory activity of rasagiline, the concomitant administration of rasagiline and dextromethorphan is not recommended.
- Serious adverse reactions have been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs), tricyclic, tetracyclic antidepressants and MAO inhibitors as well as with another selective MAO-B inhibitor. Therefore, in view of the MAO inhibitory activity of rasagiline, antidepressants should be administered with caution and in close consultation with your physician.
Pregnancy and Lactation
- No clinical data are available. Caution should be exercised when administered to a breast feeding mother.
Effects on Ability to Drive & Use Machines
No studies on Azilect® and the effects on the ability to drive and use machines have been performed. However, Azilect® is not known to cause drowsiness, so you should be able to continue driving, or operate machinery, as normal. However, if you do experience any problems in these areas you are advised to speak to your doctor.
Possible Undesirable Effects of Azilect®
Although Azilect® is generally well tolerated, as with all medicines there can be side effects. When people have taken Azilect® on its own (without levodopa), the most commonly reported side effects have been headache, aching joints, indigestion, flu-like symptoms and depression.When taken with levodopa, the most common reports were of uncontrolled movements and accidental falls. These effects may be due to the increase in dopamine caused by Azilect®, so always report such problems to your doctor. They may be able to tailor your other treatments to relieve the problem.
Overdose
- If you think that you, or anyone else, may have taken too many Azilect® tablets, contact your doctor or pharmacist immediately. If follow-up action is required, take the Azilect® carton with you to show the doctor or pharmacist.
Pharmacological Properties of Azilect®
Azilect® is a potent, irreversible MAO-B selective inhibitor. Azilect® blocks the breakdown of dopamine in the brain and hence increases the levels of dopamine available. Azilect®, when used in combination with levodopa treatment increases the availability of dopamine by preventing the levodopa-derived dopamine from being broken down.
Pharmaceutical Particulars of Azilect®
Shelf Life
- Azilect® should not be used after the expiry date on the carton.
Special precautions for storage
- Azilect® should be stored in its original package and not above 25°C. This is best achieved in a cupboard to avoid the pack getting hot in direct sunlight.
- Always keep Azilect® out of reach and sight of children.
Product Information Downloads
Patient Information
The information on this page printout is a general summary of the Azilect® medication product.
Please click on the links below to download more detailed information on the specific Azilect® medication, its handling and use.
Links go to the electronic Medicines Compendium (eMC) website.
Further detailed information on the specific Azilect® medication, its handling and use can be downloaded via the electronic Medicines Compendium (eMC) website (http://emc.medicines.org.uk/):
UK Patient Information Leaflets (PIL)
UK Summary of Product Characteristics (SPC)
Please note that SPCs are designed for healthcare professionals.
European Public Assessment Report
Further detailed information on the Azilect® medication, its handling and use can also be downloaded via the European Medicines Agency (EMEA) website (www.emea.europa.eu):
Links below go to the The European Medicines Agency (EMEA) website.
Useful Links & References
- EMEA European Public Assessment Report (EPAR) for Azilect®: http://www.emea.europa.eu/humandocs/Humans/EPAR/azilect/azilect.htm
- www.azilect.com (aimed at Healthcare Professionals)
- www.tevapharm.com
- www.tevaneuroscience.com
- www.lundbeck.com
Further Information
Teva Pharmaceuticals Ltd
The Gate House
Gatehouse Way
Aylesbury
Bucks
HP19 8DB
UK
Telephone: +44 (0)1296 719 768
Facsimile: +44 (0)1296 719 769
Medical Information e-mail: Med.info@tevapharma.co.uk
Marketing Authorisation Holder
Teva Pharma GmbH
Kandelstr 10
D-79199 Kirchzarten
Germany
